BOYNTON BEACH, Fla., Feb. 28, 2019 /PRNewswire/ -- The South Florida Bone Marrow/Stem Cell Transplant Institute DBAMaharaj Institute of Immune Regenerative Medicine in Boynton Beach, Florida, is conducting a "Phase 1/2 Clinical Study Evaluating the Safety and Efficacy of Fresh Frozen Plasma (GMFFP) from young healthy donors ages 18 to 35, who have received Granulocyte - Colony Stimulating Factor (G-CSF) to Ameliorate Frailty and Enhance the Immune Risk Profile in Older Individuals."
This Study is under an FDA (Food and Drug Administration) IND (Investigational New Drug Application) and is IRB (Institutional Review Board) approved as per the FDA guidelines. We are following all the FDA guidelines and have a Principal Investigator overseeing the study. The FDA has issued an IND number for the study and a copy of this FDA communication, acknowledging the IND is available on request to qualified consumers considering treatment. Study participants are not being charged for the treatments, the follow up or treatment side effects associated with this study.
View original content:http://www.prnewswire.com/news-releases/young-blood-clinical-study-at-the-maharaj-institute-in-florida-300803654.html
SOURCE Maharaj Institute of Immune Regenerative Medicine
Subscribe to our Free Newsletters!